Literature DB >> 19655183

The welfare costs of HIV/AIDS in eastern Europe: an empirical assessment using the economic value-of-life approach.

Julia Fimpel1, Michael Stolpe.   

Abstract

Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an inter-temporal optimisation model to determine the aggregate welfare loss from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of 3%, we find a total welfare loss for the whole region that exceeds US $800 billion, approximately 10% of the region's annual GDP between 1995 and 2001. Although prevalence and incidence rates diverge sharply between countries-with central Europe far less affected than major countries in the Commonwealth of Independent States and the Baltics-the epidemic is likely to spread to all countries unless a coherent strategy of prevention and treatment is backed up by substantial increases in healthcare investments. The sheer size of this task and the international nature of the epidemic render this one of the most important current challenges for all of Europe.

Entities:  

Mesh:

Year:  2009        PMID: 19655183     DOI: 10.1007/s10198-009-0177-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  9 in total

Review 1.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.

Authors:  Sally Blower; Erin Bodine; James Kahn; Willi McFarland
Journal:  AIDS       Date:  2005-01-03       Impact factor: 4.177

2.  The economics of HIV/AIDS in low-income countries: the case for prevention.

Authors:  David Canning
Journal:  J Econ Perspect       Date:  2006

3.  Obstacles in provision of anti-retroviral treatment to drug users in Central and Eastern Europe and Central Asia: a regional overview.

Authors:  Natalia Bobrova; Anya Sarang; Raminta Stuikyte; Konstantin Lezhentsev
Journal:  Int J Drug Policy       Date:  2007-03-21

4.  Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework.

Authors:  Sergio Bautista-Arredondo; Paola Gadsden; Jeffrey E Harris; Stefano M Bertozzi
Journal:  AIDS       Date:  2008-07       Impact factor: 4.177

5.  Making HIV prevention programmes work.

Authors:  Stefano M Bertozzi; Marie Laga; Sergio Bautista-Arredondo; Alex Coutinho
Journal:  Lancet       Date:  2008-08-05       Impact factor: 79.321

Review 6.  Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.

Authors:  Bradley M Mathers; Louisa Degenhardt; Benjamin Phillips; Lucas Wiessing; Matthew Hickman; Steffanie A Strathdee; Alex Wodak; Samiran Panda; Mark Tyndall; Abdalla Toufik; Richard P Mattick
Journal:  Lancet       Date:  2008-09-23       Impact factor: 79.321

7.  Population-based time preferences for future health outcomes.

Authors:  T G Ganiats; R T Carson; R M Hamm; S B Cantor; W Sumner; S J Spann; M D Hagen; C Miller
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

8.  The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries.

Authors:  John Stover; Stefano Bertozzi; Juan-Pablo Gutierrez; Neff Walker; Karen A Stanecki; Robert Greener; Eleanor Gouws; Catherine Hankins; Geoff P Garnett; Joshua A Salomon; J Ties Boerma; Paul De Lay; Peter D Ghys
Journal:  Science       Date:  2006-02-02       Impact factor: 47.728

9.  The natural history of HIV-1 infection in young Thai men after seroconversion.

Authors:  Ram Rangsin; Joseph Chiu; Chirasak Khamboonruang; Narongrid Sirisopana; Sakol Eiumtrakul; Arthur E Brown; Merlin Robb; Chris Beyrer; Cholticha Ruangyuttikarn; Lauri E Markowitz; Kenrad E Nelson
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.